Imatinib mesylate (STI-571, Gleevec, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is now used worldwide for the treatment of chronic myelogenous leukemia (CML) with great success; however, CML often progresses or relapses because of the development of imatinib resistance after long-term treatment. The main cause for imatinib resistance is the acquisition of point mutations in the genetic sequences encoding the Abl kinase domain. 1 Therefore, the discovery and development of a new generation of Bcr-Abl inhibitors capable of overriding imatinib resistance is of utmost importance.
On the basis of the crystallographic structure of the imatinib-Abl complex, we identified a novel inhibitor of Bcr-Abl called HH-GV-678 ( Figure 1a ). The kinase activities of c-Abl, PDGFRb (platelet derived growth factor receptor-b) and c-Kit were inhibited by HH-GV-678 with IC 50 values of 1.2 ± 0.7, 307.6±259.0 and 665.5±306.8 nM; however, this drug had no effect on the kinase activities of vascular endothelial growth factor receptor 2/kinase insert domain receptor (VEGFR2/KDR), Flt3, Ret, VEGFR3, c-Src, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Imatinib had IC 50 values of 100.9 ± 91.8, 201.8 ± 23.6 and 361.8±40.0 nM for c-Abl, PDGFRb and c-Kit, respectively. Consistent with the in vitro results of a kinase assay, HH-GV-678 completely blocked cellular Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation in K562 leukemia cells, with much more potent activity than did imatinib (30 vs 300 nM) (Figure 1b) . However, HH-GV-678 inhibited the phosphorylations of c-Kit and PDGFRb with less potency (Supplementary Figure 1) and had no effect on the phosphorylation of EGFR, VEGFR, c-Src or HER2 (Supplementary Figure 2) . These data indicate that HH-GV-678 is a selective inhibitor of the c-Abl kinase and has much stronger activity than imatinib. were incubated with HH-GV-678 or imatinib for 3 h. Total cell lysates were analyzed by western blotting, and the levels of phospho-and un-phosphoproteins were determined using specific antibodies.
To determine whether HH-GV-678 can override imatinib resistance conferred by point mutations in Bcr-Abl, we generated a series of 32D cell lines stably expressing nonmutant Bcr-Abl or the Bcr-Abl mutants Q252H, Y253F, E255K, M351T, H396P and T315I (plasmids kindly provided by Dr Brian Druker, Oregon Health Sciences University, Portland, OR, USA). Consistent with previous findings, 2 these Bcr-Abl mutants were resistant to imatinib. HH-GV-678 inhibited the autophosphorylation of imatinib-resistant Bcr-Abl mutants to a similar extent as nonmutated Bcr-Abl (Figure1c and Supplementary  Figure 3 ). However, HH-GV-678 did not inhibit autophosphorylation of a Bcr-Abl T315I mutant expressed in 32D cells ( Figure 1d ).
Next, we determined the effects of HH-GV-678 on the proliferation of leukemia cells expressing nonmutated or mutated Bcr-Abl. As shown in Table 1 , HH-GV-678 treatment significantly suppressed the proliferation of Bcr-Abl-positive CML K562 cells and 32D cells expressing nonmutant Bcr-Abl. The proliferation inhibitory activity of HH-GV-678 was B32-to 58-fold more potent than that of imatinib and two-to five-fold more potent than that of nilotinib, but five-to six-fold less potent than that of dasatinib. Consistent with the in vitro kinase assay and cellular Bcr-Abl phosphorylation, 32D cells expressing the Q252H, Y253F, E255K, M351T, H396P and T315I Bcr-Abl mutants were resistant to imatinib treatment, but still sensitive to HH-GV-678, except for the T315I mutant (Table 1) .
To further extend these in vitro results, we conducted an in vivo efficacy study. The CML K562 tumor models were Table 1 Comparative effects of HH-GV-678, imatinib, nilotinib and dasatinib on the proliferation of cells expressing nonmutated or mutated Bcr-Abl, as assessed by the MTT assay Letters to the Editor established by subcutaneously injecting K562 cells into nude mice. Our findings revealed that HH-GV-678 significantly, and in a dose-dependent manner, inhibited the growth of K562 xenografts and induced regression in all tumors at a daily dose of 75 mg/kg for nine days. In contrast, imatinib only induced regression in two of eight tumors at a daily dose of 300 mg/kg (150 mg/kg, twice a day) for 14 days (Figure 2a ). In addition, HH-GV-678 significantly improved the body weight of tumorbearing mice. These effects of HH-GV-678 could translate into a survival benefit for tumor-bearing mice. As shown in Figure 2b , vehicle-treated mice largely died owing to rapid growth of the K562 xenografts, and had a median survival time of 25.5 days. The HH-GV-678 treatment effectively and dose-dependently inhibited tumor growth and prolonged the survival of these tumor-bearing mice. The median survival time was prolonged from 25.5 to 47.5 days when mice were given a daily dose of 75 mg/kg for 14 days. In contrast, imatinib prolonged the median survival time from 25.5 to 33 days when mice were given a daily dose of 300 mg/kg (150 mg/kg, twice a day). Most mice died before day 42; however, two of eight mice in the group who were receiving 75 mg/kg HH-GV-678 remained alive without any observable tumors on day 60.
To investigate the efficacy of HH-GV-678 against imatinibresistant CML in vivo, we established a systemic CML model by injecting imatinib-resistant 32D-H396P cells into the tail veins of nude mice. Mice injected with 32D-H396P cells became morbid, developed hind-leg paralysis and died within 14-15 days. Pathological studies revealed that these mice were seriously hepatomegalic (that is, 1.94-fold in weight) and splenomegalic (that is, 6.0-fold in weight) compared with normal mice. Treatment with HH-GV-678 for 13 days (100 mg/kg) significantly blocked the hind-leg paralysis, and reduced the hepatomegaly (P ¼ 0.002) and splenomegaly (P ¼ 0.03) in these leukemic mice (Supplementary Figure 4) . Consistent with the results described above, the survival of HH-GV-678-treated mice was significantly prolonged compared with both untreated and imatinib-treated mice (Figure 2c) .
To elucidate the potential mechanisms underlying the superior antitumor effects of HH-GV-678, we compared the effects of HH-GV-678 and imatinib on Bcr-Abl autophosphorylation in K562 xenograft tissues. Treatment with HH-GV-678 significantly inhibited Bcr-Abl phosphorylation within 2 h after treatment, and this inhibitory effect was maintained for 24 h at a dose of 75 mg/kg. In contrast, and consistent with previous findings, 3 although imatinib (150 mg/kg) inhibited Bcr-Abl phosphorylation within 2 h of drug treatment, this inhibition only lasted for 6 h (Supplementary Figure 5) . We believe that the differential effect on target inhibition may contribute to the superior antitumor effects of HH-GV-678.
In conclusion, we have characterized HH-GV-678 as a novel inhibitor of Bcr-Abl that significantly inhibits Bcr-Abl activity, overrides imatinib resistance mediated by point mutations in Bcr-Abl and notably outperforms imatinib both in vitro and in vivo. Thus, our findings suggest that HH-GV-678 is a promising candidate for the treatment of CML, particularly for patients who develop imatinib resistance as a result of mutations in the Bcr-Abl kinase domain. Currently, HH-GV-678 is undergoing phase I clinical trials in China.
Conflicts of interest
The authors declare no conflict of interest.
